메뉴 건너뛰기




Volumn 5, Issue , 2012, Pages 67-76

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: Status and prospects

Author keywords

Cancer; Novel treatment; T cell lymphoma; Vorinostat

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BORTEZOMIB; CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PLACEBO; TAMOXIFEN; VORINOSTAT;

EID: 84861384893     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S23874     Document Type: Review
Times cited : (17)

References (102)
  • 2
    • 0036386359 scopus 로고    scopus 로고
    • Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation
    • Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res. 2002;86:41-65.
    • (2002) Adv Cancer Res , vol.86 , pp. 41-65
    • Lehrmann, H.1    Pritchard, L.L.2    Harel-Bellan, A.3
  • 3
    • 0035063182 scopus 로고    scopus 로고
    • Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin
    • Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 2001;10:693-698.
    • (2001) Hum Mol Genet , vol.10 , pp. 693-698
    • Wade, P.A.1
  • 4
    • 28644440158 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Discovery and development as anticancer agents
    • Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497-1511.
    • (2005) Expert Opin Investig Drugs , vol.14 , pp. 1497-1511
    • Marks, P.A.1    Dokmanovic, M.2
  • 5
    • 3943054839 scopus 로고    scopus 로고
    • The Sir2 family of protein deacetylases
    • Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417-435.
    • (2004) Annu Rev Biochem , vol.73 , pp. 417-435
    • Blander, G.1    Guarente, L.2
  • 6
    • 0037067696 scopus 로고    scopus 로고
    • Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family
    • Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 2002;277:25748-25755.
    • (2002) J Biol Chem , vol.277 , pp. 25748-25755
    • Gao, L.1    Cueto, M.A.2    Asselbergs, F.3    Atadja, P.4
  • 7
    • 0030798245 scopus 로고    scopus 로고
    • Histone acetylation in chromatin structure and transcription
    • Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349-352.
    • (1997) Nature , vol.389 , pp. 349-352
    • Grunstein, M.1
  • 8
    • 28044471827 scopus 로고    scopus 로고
    • Acetylation and deacetylation of non-histone proteins
    • Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15-23.
    • (2005) Gene , vol.363 , pp. 15-23
    • Glozak, M.A.1    Sengupta, N.2    Zhang, X.3    Seto, E.4
  • 9
    • 34547864236 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Molecular mechanisms of action
    • Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541-5552.
    • (2007) Oncogene , vol.26 , pp. 5541-5552
    • Xu, W.S.1    Parmigiani, R.B.2    Marks, P.A.3
  • 10
    • 0034045040 scopus 로고    scopus 로고
    • Histone deacetylases, transcriptional control, and cancer
    • Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000;184:1-16.
    • (2000) J Cell Physiol , vol.184 , pp. 1-16
    • Cress, W.D.1    Seto, E.2
  • 12
    • 1842631408 scopus 로고    scopus 로고
    • Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer
    • Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59:177-189.
    • (2004) Prostate , vol.59 , pp. 177-189
    • Halkidou, K.1    Gaughan, L.2    Cook, S.3    Leung, H.Y.4    Neal, D.E.5    Robson, C.N.6
  • 13
    • 0035676731 scopus 로고    scopus 로고
    • Expression profile of histone deacetylase 1 in gastric cancer tissues
    • Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001;92: 1300-1304.
    • (2001) Jpn J Cancer Res , vol.92 , pp. 1300-1304
    • Choi, J.H.1    Kwon, H.J.2    Yoon, B.I.3
  • 14
    • 33744956666 scopus 로고    scopus 로고
    • Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
    • Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281:13548-13558.
    • (2006) J Biol Chem , vol.281 , pp. 13548-13558
    • Wilson, A.J.1    Byun, D.S.2    Popova, N.3
  • 15
    • 26244441525 scopus 로고    scopus 로고
    • Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
    • Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat. 2005;94:11-16.
    • (2005) Breast Cancer Res Treat , vol.94 , pp. 11-16
    • Zhang, Z.1    Yamashita, H.2    Toyama, T.3
  • 17
    • 17144378591 scopus 로고    scopus 로고
    • Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
    • Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005;12:395-404.
    • (2005) Cell Death Differ , vol.12 , pp. 395-404
    • Huang, B.H.1    Laban, M.2    Leung, C.H.3
  • 18
    • 21044447215 scopus 로고    scopus 로고
    • Increased expression of histone deacetylase 2 is found in human gastric cancer
    • Song J, Noh JH, Lee JH, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005;113:264-268.
    • (2005) APMIS , vol.113 , pp. 264-268
    • Song, J.1    Noh, J.H.2    Lee, J.H.3
  • 19
    • 33644856123 scopus 로고    scopus 로고
    • Epigenetic therapy of cancer: Past, present and future
    • Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37-50.
    • (2006) Nat Rev Drug Discov , vol.5 , pp. 37-50
    • Yoo, C.B.1    Jones, P.A.2
  • 20
    • 1542588471 scopus 로고    scopus 로고
    • Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
    • Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A. 1996;93:5705-5708.
    • (1996) Proc Natl Acad Sci U S A , vol.93 , pp. 5705-5708
    • Richon, V.M.1    Webb, Y.2    Merger, R.3
  • 21
    • 36148950997 scopus 로고    scopus 로고
    • FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
    • Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247-1252.
    • (2007) Oncologist , vol.12 , pp. 1247-1252
    • Mann, B.S.1    Johnson, J.R.2    Cohen, M.H.3    Justice, R.4    Pazdur, R.5
  • 22
    • 33847258674 scopus 로고    scopus 로고
    • Discovery and development of SAHA as an anticancer agent
    • Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351-1356.
    • (2007) Oncogene , vol.26 , pp. 1351-1356
    • Marks, P.A.1
  • 23
    • 0028116705 scopus 로고
    • Inducing differentiation of transformed cells with hybrid polar compounds: A cell cycle-dependent process
    • Marks PA, Richon VM, Kiyokawa H, Rifkind RA. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci U S A. 1994;91: 10251-10254.
    • (1994) Proc Natl Acad Sci U S A , vol.91 , pp. 10251-10254
    • Marks, P.A.1    Richon, V.M.2    Kiyokawa, H.3    Rifkind, R.A.4
  • 25
    • 0021980514 scopus 로고
    • Molecular and cellular mechanisms of leukemic hemopoietic cell differentiation: An analysis of the Friend system
    • Tsiftsoglou AS, Wong W. Molecular and cellular mechanisms of leukemic hemopoietic cell differentiation: an analysis of the Friend system. Anticancer Res. 1985;5:81-99.
    • (1985) Anticancer Res , vol.5 , pp. 81-99
    • Tsiftsoglou, A.S.1    Wong, W.2
  • 26
    • 0026446246 scopus 로고
    • Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A phase II clinical trial with a differentiation-inducing agent
    • Andreeff M, Stone R, Michaeli J, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 1992;80:2604-2609.
    • (1992) Blood , vol.80 , pp. 2604-2609
    • Andreeff, M.1    Stone, R.2    Michaeli, J.3
  • 27
    • 0032539890 scopus 로고    scopus 로고
    • A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
    • Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998;95:3003-3007.
    • (1998) Proc Natl Acad Sci U S A , vol.95 , pp. 3003-3007
    • Richon, V.M.1    Emiliani, S.2    Verdin, E.3
  • 28
    • 73949128107 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in cancer therapy
    • Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459-5468.
    • (2009) J Clin Oncol , vol.27 , pp. 5459-5468
    • Lane, A.A.1    Chabner, B.A.2
  • 29
    • 0024996768 scopus 로고
    • Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
    • Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174-17179.
    • (1990) J Biol Chem , vol.265 , pp. 17174-17179
    • Yoshida, M.1    Kijima, M.2    Akita, M.3    Beppu, T.4
  • 30
    • 33748063974 scopus 로고    scopus 로고
    • A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    • Giles F, Fischer T, Cortes J, et al. A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628-4635.
    • (2006) Clin Cancer Res , vol.12 , pp. 4628-4635
    • Giles, F.1    Fischer, T.2    Cortes, J.3
  • 31
    • 51649126841 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
    • Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14:4500-4510.
    • (2008) Clin Cancer Res , vol.14 , pp. 4500-4510
    • Ellis, L.1    Pan, Y.2    Smyth, G.K.3
  • 32
    • 70349194470 scopus 로고    scopus 로고
    • Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma
    • Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol. 2009;147: 97-101.
    • (2009) Br J Haematol , vol.147 , pp. 97-101
    • Dickinson, M.1    Ritchie, D.2    Deangelo, D.J.3
  • 33
    • 79960197509 scopus 로고    scopus 로고
    • A Phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma
    • Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. A Phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011;29:451-455.
    • (2011) Cancer Invest , vol.29 , pp. 451-455
    • Hainsworth, J.D.1    Infante, J.R.2    Spigel, D.R.3    Arrowsmith, E.R.4    Boccia, R.V.5    Burris, H.A.6
  • 34
    • 77951884767 scopus 로고    scopus 로고
    • A Phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
    • Rathkopf D, Wong BY, Ross RW, et al. A Phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2010;66:181-189.
    • (2010) Cancer Chemother Pharmacol , vol.66 , pp. 181-189
    • Rathkopf, D.1    Wong, B.Y.2    Ross, R.W.3
  • 35
    • 49349104503 scopus 로고    scopus 로고
    • A Phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
    • Gimsing P, Hansen M, Knudsen LM, et al. A Phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81:170-176.
    • (2008) Eur J Haematol , vol.81 , pp. 170-176
    • Gimsing, P.1    Hansen, M.2    Knudsen, L.M.3
  • 36
    • 38949146399 scopus 로고    scopus 로고
    • A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
    • Steele NL, Plumb JA, Vidal L, et al. A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008;14:804-810.
    • (2008) Clin Cancer Res , vol.14 , pp. 804-810
    • Steele, N.L.1    Plumb, J.A.2    Vidal, L.3
  • 37
    • 79956325272 scopus 로고    scopus 로고
    • Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors
    • Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29:2052-2059.
    • (2011) J Clin Oncol , vol.29 , pp. 2052-2059
    • Giaccone, G.1    Rajan, A.2    Berman, A.3
  • 38
    • 77952585540 scopus 로고    scopus 로고
    • Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
    • Mackay HJ, Hirte H, Colgan T, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010;46:1573-1579.
    • (2010) Eur J Cancer , vol.46 , pp. 1573-1579
    • Mackay, H.J.1    Hirte, H.2    Colgan, T.3
  • 39
    • 61549123363 scopus 로고    scopus 로고
    • Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
    • Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009;4:97-101.
    • (2009) J Thorac Oncol , vol.4 , pp. 97-101
    • Ramalingam, S.S.1    Belani, C.P.2    Ruel, C.3
  • 40
    • 0036735385 scopus 로고    scopus 로고
    • FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases
    • Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62:4916-4921.
    • (2002) Cancer Res , vol.62 , pp. 4916-4921
    • Furumai, R.1    Matsuyama, A.2    Kobashi, N.3
  • 41
    • 79960185557 scopus 로고    scopus 로고
    • Romidepsin (Istodax, NSC-630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma
    • VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC-630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011;64:525-531.
    • (2011) J Antibiot (Tokyo) , vol.64 , pp. 525-531
    • Vandermolen, K.M.1    McCulloch, W.2    Pearce, C.J.3    Oberlies, N.H.4
  • 42
    • 19944432566 scopus 로고    scopus 로고
    • A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
    • Byrd JC, Marcucci G, Parthun MR, et al. A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959-967.
    • (2005) Blood , vol.105 , pp. 959-967
    • Byrd, J.C.1    Marcucci, G.2    Parthun, M.R.3
  • 44
    • 40749101544 scopus 로고    scopus 로고
    • Clinical and molecular responses in lung cancer patients receiving romidepsin
    • Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin Cancer Res. 2008;14:188-198.
    • (2008) Clin Cancer Res , vol.14 , pp. 188-198
    • Schrump, D.S.1    Fischette, M.R.2    Nguyen, D.M.3
  • 45
    • 77958185126 scopus 로고    scopus 로고
    • Cancer and Leukemia Group B. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)
    • Otterson GA, Hodgson L, Pang H, Vokes EE; Cancer and Leukemia Group B. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010;5:1644-1648.
    • (2010) J Thorac Oncol , vol.5 , pp. 1644-1648
    • Otterson, G.A.1    Hodgson, L.2    Pang, H.3    Vokes, E.E.4
  • 46
    • 38949144400 scopus 로고    scopus 로고
    • Tolerability, pharmacodynamics, and pharmacokinetic studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
    • Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetic studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008;14:826-832.
    • (2008) Clin Cancer Res , vol.14 , pp. 826-832
    • Klimek, V.M.1    Fircanis, S.2    Maslak, P.3
  • 47
    • 68649119641 scopus 로고    scopus 로고
    • Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336)
    • Whitehead RP, Rankin C, Hoff PM, et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2009;27:469-475.
    • (2009) Invest New Drugs , vol.27 , pp. 469-475
    • Whitehead, R.P.1    Rankin, C.2    Hoff, P.M.3
  • 48
    • 70549105748 scopus 로고    scopus 로고
    • Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
    • Molife LR, Attard G, Fong PC, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010;21:109-113.
    • (2010) Ann Oncol , vol.21 , pp. 109-113
    • Molife, L.R.1    Attard, G.2    Fong, P.C.3
  • 49
    • 78650992102 scopus 로고    scopus 로고
    • Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
    • Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117:336-342.
    • (2011) Cancer , vol.117 , pp. 336-342
    • Niesvizky, R.1    Ely, S.2    Mark, T.3
  • 50
    • 79959956310 scopus 로고    scopus 로고
    • A Phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
    • Iwamoto FM, Lamborn KR, Kuhn JG, et al. A Phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011;13:509-516.
    • (2011) Neuro Oncol , vol.13 , pp. 509-516
    • Iwamoto, F.M.1    Lamborn, K.R.2    Kuhn, J.G.3
  • 51
    • 21244458052 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
    • Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23:3912-3922.
    • (2005) J Clin Oncol , vol.23 , pp. 3912-3922
    • Ryan, Q.C.1    Headlee, D.2    Acharya, M.3
  • 52
    • 51649091668 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
    • Gore L, Rothenberg ML, O'Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008;14:4517-4525.
    • (2008) Clin Cancer Res , vol.14 , pp. 4517-4525
    • Gore, L.1    Rothenberg, M.L.2    O'Bryant, C.L.3
  • 53
    • 33947581039 scopus 로고    scopus 로고
    • Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
    • Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007;109:2781-2790.
    • (2007) Blood , vol.109 , pp. 2781-2790
    • Gojo, I.1    Jiemjit, A.2    Trepel, J.B.3
  • 54
    • 58149377828 scopus 로고    scopus 로고
    • Multicenter Phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)- carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
    • Hauschild A, Trefzer U, Garbe C, et al. Multicenter Phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)- carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 2008;18:274-278.
    • (2008) Melanoma Res , vol.18 , pp. 274-278
    • Hauschild, A.1    Trefzer, U.2    Garbe, C.3
  • 55
    • 78650848615 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in the treatment of lymphoma
    • Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med. 2010;10:462-470.
    • (2010) Discov Med , vol.10 , pp. 462-470
    • Lemoine, M.1    Younes, A.2
  • 56
    • 0037158513 scopus 로고    scopus 로고
    • Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications
    • Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673-5683.
    • (2002) Oncogene , vol.21 , pp. 5673-5683
    • Mitsiades, C.S.1    Mitsiades, N.2    Poulaki, V.3
  • 57
    • 9144220841 scopus 로고    scopus 로고
    • Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
    • Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci U S A. 2004;101:540-545.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 540-545
    • Mitsiades, C.S.1    Mitsiades, N.S.2    McMullan, C.J.3
  • 58
    • 34948830177 scopus 로고    scopus 로고
    • Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
    • Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood. 2007;110:2667-2673.
    • (2007) Blood , vol.110 , pp. 2667-2673
    • Kawamata, N.1    Chen, J.2    Koeffler, H.P.3
  • 59
    • 33847372445 scopus 로고    scopus 로고
    • Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects on gene expression and growth of glioma cells in vitro and in vivo
    • Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res. 2007;13: 1045-1052.
    • (2007) Clin Cancer Res , vol.13 , pp. 1045-1052
    • Yin, D.1    Ong, J.M.2    Hu, J.3
  • 60
    • 0842277812 scopus 로고    scopus 로고
    • Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
    • Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A. 2004;101:1241-1246.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 1241-1246
    • Gui, C.Y.1    Ngo, L.2    Xu, W.S.3    Richon, V.M.4    Marks, P.A.5
  • 61
    • 0034730127 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor selectively induces p21WAF1 expression and geneassociated histone acetylation
    • Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and geneassociated histone acetylation. Proc Natl Acad Sci U S A. 2000;97: 10014-10019.
    • (2000) Proc Natl Acad Sci U S A , vol.97 , pp. 10014-10019
    • Richon, V.M.1    Sandhoff, T.W.2    Rifkind, R.A.3    Marks, P.A.4
  • 62
    • 85047699941 scopus 로고    scopus 로고
    • Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
    • Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21:427-436.
    • (2002) Oncogene , vol.21 , pp. 427-436
    • Deroanne, C.F.1    Bonjean, K.2    Servotte, S.3
  • 63
    • 22844432021 scopus 로고    scopus 로고
    • Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors
    • Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005;280:26729-26734.
    • (2005) J Biol Chem , vol.280 , pp. 26729-26734
    • Bali, P.1    Pranpat, M.2    Bradner, J.3
  • 64
    • 34548075217 scopus 로고    scopus 로고
    • Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: A result of hyperacetylation and inhibition of chaperone function of heat shock protein 90
    • Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res. 2007;13:4882-4890.
    • (2007) Clin Cancer Res , vol.13 , pp. 4882-4890
    • Fiskus, W.1    Ren, Y.2    Mohapatra, A.3
  • 66
    • 0016773923 scopus 로고
    • Cutaneous T-cell lymphomas: The Sézary syndrome, mycosis fungoides, and related disorders
    • Lutzner AM, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med. 1975;83:534-552.
    • (1975) Ann Intern Med , vol.83 , pp. 534-552
    • Lutzner, A.M.1    Edelson, R.2    Schein, P.3    Green, I.4    Kirkpatrick, C.5    Ahmed, A.6
  • 67
    • 79958708461 scopus 로고    scopus 로고
    • Therapeutic advances in cutaneous T-cell lymphoma
    • Akilov OE, Geskin L. Therapeutic advances in cutaneous T-cell lymphoma. Skin Therapy Lett. 2011;16:1-5.
    • (2011) Skin Therapy Lett , vol.16 , pp. 1-5
    • Akilov, O.E.1    Geskin, L.2
  • 68
    • 21244464349 scopus 로고    scopus 로고
    • Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    • Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923-3931.
    • (2005) J Clin Oncol , vol.23 , pp. 3923-3931
    • Kelly, W.K.1    O'Connor, O.A.2    Krug, L.M.3
  • 69
    • 70149124715 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
    • Fujiwara Y, Yamamoto N, Yamada Y, et al. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci. 2009;100:1728-1734.
    • (2009) Cancer Sci , vol.100 , pp. 1728-1734
    • Fujiwara, Y.1    Yamamoto, N.2    Yamada, Y.3
  • 70
    • 33845996135 scopus 로고    scopus 로고
    • Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
    • Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31-39.
    • (2007) Blood , vol.109 , pp. 31-39
    • Duvic, M.1    Talpur, R.2    Ni, X.3
  • 71
    • 34547683194 scopus 로고    scopus 로고
    • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
    • Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-3115.
    • (2007) J Clin Oncol , vol.25 , pp. 3109-3115
    • Olsen, E.A.1    Kim, Y.H.2    Kuzel, T.M.3
  • 72
    • 70349633604 scopus 로고    scopus 로고
    • A phase 2 study of vorinostat in acute myeloid leukemia
    • Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009;94:1375-1382.
    • (2009) Haematologica , vol.94 , pp. 1375-1382
    • Schaefer, E.W.1    Loaiza-Bonilla, A.2    Juckett, M.3
  • 73
    • 43049092663 scopus 로고    scopus 로고
    • Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
    • Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19:964-969.
    • (2008) Ann Oncol , vol.19 , pp. 964-969
    • Crump, M.1    Coiffier, B.2    Jacobsen, E.D.3
  • 74
    • 39749103428 scopus 로고    scopus 로고
    • Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
    • Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49(3):502-507.
    • (2008) Leuk Lymphoma , vol.49 , Issue.3 , pp. 502-507
    • Richardson, P.1    Mitsiades, C.2    Colson, K.3
  • 75
    • 71849117270 scopus 로고    scopus 로고
    • Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a Phase I trial in follicular and mantle cell lymphoma
    • Watanabe T, Kato H, Kobayashi Y, et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a Phase I trial in follicular and mantle cell lymphoma. Cancer Sci. 2010;101:196-200.
    • (2010) Cancer Sci , vol.101 , pp. 196-200
    • Watanabe, T.1    Kato, H.2    Kobayashi, Y.3
  • 76
    • 79952773321 scopus 로고    scopus 로고
    • Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    • Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:1198-1203.
    • (2011) J Clin Oncol , vol.29 , pp. 1198-1203
    • Kirschbaum, M.1    Frankel, P.2    Popplewell, L.3
  • 77
    • 38149140216 scopus 로고    scopus 로고
    • Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
    • Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008;26:81-87.
    • (2008) Invest New Drugs , vol.26 , pp. 81-87
    • Blumenschein Jr., G.R.1    Kies, M.S.2    Papadimitrakopoulou, V.A.3
  • 78
    • 43049091153 scopus 로고    scopus 로고
    • Gynecologic Oncology Group. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
    • Modesitt SC, Sill M, Hoffman JS, Bender DP; Gynecologic Oncology Group. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182-186.
    • (2008) Gynecol Oncol , vol.109 , pp. 182-186
    • Modesitt, S.C.1    Sill, M.2    Hoffman, J.S.3    Bender, D.P.4
  • 79
    • 50249095068 scopus 로고    scopus 로고
    • Early Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
    • Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008;26:483-488.
    • (2008) Invest New Drugs , vol.26 , pp. 483-488
    • Vansteenkiste, J.1    van Cutsem, E.2    Dumez, H.3
  • 80
    • 72249110437 scopus 로고    scopus 로고
    • Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
    • Bradley D, Rathkopf D, Dunn R, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer. 2009;115:5541-5549.
    • (2009) Cancer , vol.115 , pp. 5541-5549
    • Bradley, D.1    Rathkopf, D.2    Dunn, R.3
  • 81
    • 67649399669 scopus 로고    scopus 로고
    • Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A Wisconsin Oncology Network Phase II study
    • Traynor AM, Dubey S, Eickhoff JC, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. J Thorac Oncol. 2009;4:522-526.
    • (2009) J Thorac Oncol , vol.4 , pp. 522-526
    • Traynor, A.M.1    Dubey, S.2    Eickhoff, J.C.3
  • 82
    • 65349141942 scopus 로고    scopus 로고
    • Phase II trial of vorinostat in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study
    • Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol. 2009;27:2052-2058.
    • (2009) J Clin Oncol , vol.27 , pp. 2052-2058
    • Galanis, E.1    Jaeckle, K.A.2    Maurer, M.J.3
  • 83
    • 58149242889 scopus 로고    scopus 로고
    • A Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study
    • Luu TH, Morgan RJ, Leong L, et al. A Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008;14:7138-7142.
    • (2008) Clin Cancer Res , vol.14 , pp. 7138-7142
    • Luu, T.H.1    Morgan, R.J.2    Leong, L.3
  • 84
    • 0042905956 scopus 로고    scopus 로고
    • Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines
    • Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2003;2:151-163.
    • (2003) Mol Cancer Ther , vol.2 , pp. 151-163
    • Glaser, K.B.1    Staver, M.J.2    Waring, J.F.3    Stender, J.4    Ulrich, R.G.5    Davidsen, S.K.6
  • 85
    • 77649183822 scopus 로고    scopus 로고
    • A Phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
    • Wilson PM, El-Khoueiry A, Iqbal S, et al. A Phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010;65:979-988.
    • (2010) Cancer Chemother Pharmacol , vol.65 , pp. 979-988
    • Wilson, P.M.1    El-Khoueiry, A.2    Iqbal, S.3
  • 86
    • 77954692325 scopus 로고    scopus 로고
    • A Phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors
    • Fakih MG, Fetterly G, Egorin MJ, et al. A Phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res. 2010;16:3786-3794.
    • (2010) Clin Cancer Res , vol.16 , pp. 3786-3794
    • Fakih, M.G.1    Fetterly, G.2    Egorin, M.J.3
  • 87
    • 65649107307 scopus 로고    scopus 로고
    • A Phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer
    • Fakih MG, Pendyala L, Fetterly G, et al. A Phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res. 2009;15:3189-3195.
    • (2009) Clin Cancer Res , vol.15 , pp. 3189-3195
    • Fakih, M.G.1    Pendyala, L.2    Fetterly, G.3
  • 88
    • 0242610850 scopus 로고    scopus 로고
    • Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA
    • Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003;63:7291-7300.
    • (2003) Cancer Res , vol.63 , pp. 7291-7300
    • Kim, M.S.1    Blake, M.2    Baek, J.H.3    Kohlhagen, G.4    Pommier, Y.5    Carrier, F.6
  • 89
    • 0037161744 scopus 로고    scopus 로고
    • HDAC6 is a microtubuleassociated deacetylase
    • Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubuleassociated deacetylase. Nature. 2002;417:455-458.
    • (2002) Nature , vol.417 , pp. 455-458
    • Hubbert, C.1    Guardiola, A.2    Shao, R.3
  • 90
    • 34250696097 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    • Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007;13:3605-3610.
    • (2007) Clin Cancer Res , vol.13 , pp. 3605-3610
    • Ramalingam, S.S.1    Parise, R.A.2    Ramanathan, R.K.3
  • 91
    • 73949140461 scopus 로고    scopus 로고
    • Carboplatin and paclitaxel in combination with either vorinostat or placebo for firstline therapy of advanced non-small-cell lung cancer
    • Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for firstline therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:56-62.
    • (2010) J Clin Oncol , vol.28 , pp. 56-62
    • Ramalingam, S.S.1    Maitland, M.L.2    Frankel, P.3
  • 92
    • 79960066445 scopus 로고    scopus 로고
    • Proteostasis regulation at the endoplasmic reticulum: A new perturbation site for targeted cancer therapy
    • Liu Y, Ye Y. Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell Res. 2011;21:867-883.
    • (2011) Cell Res , vol.21 , pp. 867-883
    • Liu, Y.1    Ye, Y.2
  • 93
    • 84859455667 scopus 로고    scopus 로고
    • Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically
    • September 2, 2011. [Epub ahead of print.]
    • Sato A, Asano T, Ito K, Sumitomo M, Asano T. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int. September 2, 2011. [Epub ahead of print.]
    • BJU Int
    • Sato, A.1    Asano, T.2    Ito, K.3    Sumitomo, M.4    Asano, T.5
  • 94
    • 68749093915 scopus 로고    scopus 로고
    • The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis
    • Zhang QL, Wang L, Zhang YW, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia. 2009;23:1507-1514.
    • (2009) Leukemia , vol.23 , pp. 1507-1514
    • Zhang, Q.L.1    Wang, L.2    Zhang, Y.W.3
  • 95
    • 0242493856 scopus 로고    scopus 로고
    • The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571
    • Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 2003;102:3765-3774.
    • (2003) Blood , vol.102 , pp. 3765-3774
    • Yu, C.1    Rahmani, M.2    Conrad, D.3    Subler, M.4    Dent, P.5    Grant, S.6
  • 96
    • 38049126172 scopus 로고    scopus 로고
    • Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
    • Heider U, von Metzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol. 2008;80:133-142.
    • (2008) Eur J Haematol , vol.80 , pp. 133-142
    • Heider, U.1    von Metzler, I.2    Kaiser, M.3
  • 97
    • 34249993174 scopus 로고    scopus 로고
    • SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib
    • Emanuele S, Lauricella M, Carlisi D, et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis. 2007;12:1327-1338.
    • (2007) Apoptosis , vol.12 , pp. 1327-1338
    • Emanuele, S.1    Lauricella, M.2    Carlisi, D.3
  • 98
    • 69349097803 scopus 로고    scopus 로고
    • Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma
    • Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res. 2009;15:5250-5257.
    • (2009) Clin Cancer Res , vol.15 , pp. 5250-5257
    • Badros, A.1    Burger, A.M.2    Philip, S.3
  • 99
    • 82955170653 scopus 로고    scopus 로고
    • Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
    • Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011;130:437-447.
    • (2011) Breast Cancer Res Treat , vol.130 , pp. 437-447
    • Thomas, S.1    Thurn, K.T.2    Biçaku, E.3    Marchion, D.C.4    Münster, P.N.5
  • 100
    • 79958084461 scopus 로고    scopus 로고
    • A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
    • Munster PN, Thurn KT, Thomas S, et al. A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104:1828-1835.
    • (2011) Br J Cancer , vol.104 , pp. 1828-1835
    • Munster, P.N.1    Thurn, K.T.2    Thomas, S.3
  • 101
    • 80052927231 scopus 로고    scopus 로고
    • Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy
    • Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011;117:4424-4438.
    • (2011) Cancer , vol.117 , pp. 4424-4438
    • Chen, M.Y.1    Liao, W.S.2    Lu, Z.3
  • 102
    • 79952710830 scopus 로고    scopus 로고
    • Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas
    • Stathis A, Hotte SJ, Chen EX, et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res. 2011;17: 1582-1590.
    • (2011) Clin Cancer Res , vol.17 , pp. 1582-1590
    • Stathis, A.1    Hotte, S.J.2    Chen, E.X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.